Warwick SAS Medical Limited - Accounts to registrar (filleted) - small 18.2

REGISTERED NUMBER: 12900152 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD

23 SEPTEMBER 2020 TO 30 JUNE 2021

FOR

WARWICK SAS MEDICAL LIMITED

Page

Company Information

1

Abridged Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

D F Booth

Mrs A S Green

Mrs C A Robertson

SECRETARY:

Mrs A S Green

REGISTERED OFFICE:

Warwick House

Heathcote Way

Warwick

Warwickshire

CV34 6TE

REGISTERED NUMBER:

12900152 (England and Wales)

FIXED ASSETS

Investments

4

3,800,081

CURRENT ASSETS

Debtors

70,000

CREDITORS

Amounts falling due within one year

70,000

NET CURRENT LIABILITIES

-

TOTAL ASSETS LESS CURRENT LIABILITIES

3,800,081

CAPITAL AND RESERVES

Called up share capital

5

225

Share premium

3,799,856

SHAREHOLDERS' FUNDS

3,800,081

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 June 2021.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 June 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the period ended 30 June 2021 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 3 November 2021 and were signed on its behalf by:

D F Booth - Director

1.	STATUTORY INFORMATION

Warwick SAS Medical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

The financial statements are presented in sterling which is the functional currency of the company and is rounded to the nearest £1.

Preparation of consolidated financial statements

The financial statements contain information about Warwick SAS Medical Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 3 .

4.	FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:

Totals

£

COST

Additions

3,800,081

At 30 June 2021

3,800,081

NET BOOK VALUE

At 30 June 2021

3,800,081

5.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

value:

£

13,463

Ordinary A

1p

135

90

Ordinary B

£1

90

225

90 Ordinary B shares of £1 each were allotted and fully paid for cash at par during the period.

13,463 Ordinary A shares of 1p each were allotted as fully paid at a premium of £28,224.44 per share during the period.

6.	RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.